Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 8.8% – What’s Next?

Capricor Therapeutics Inc (NASDAQ:CAPR)’s stock price traded down 8.8% on Tuesday . The stock traded as low as $17.85 and last traded at $17.91. 1,103,225 shares traded hands during mid-day trading, a decline of 4% from the average session volume of 1,147,935 shares. The stock had previously closed at $19.64.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the stock. Maxim Group raised their target price on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a report on Wednesday, September 25th. Oppenheimer reaffirmed an “outperform” rating and issued a $15.00 target price on shares of Capricor Therapeutics in a report on Monday, September 23rd. HC Wainwright reaffirmed a “buy” rating and issued a $77.00 target price on shares of Capricor Therapeutics in a report on Thursday, November 14th. Piper Sandler assumed coverage on shares of Capricor Therapeutics in a report on Monday, October 21st. They issued an “overweight” rating and a $35.00 target price on the stock. Finally, Cantor Fitzgerald raised their target price on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday, November 14th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $34.50.

Capricor Therapeutics Price Performance

The firm has a market capitalization of $578.38 million, a PE ratio of -12.00 and a beta of 3.98. The business’s 50-day moving average price is $18.50 and its 200-day moving average price is $9.63.

Insider Activity at Capricor Therapeutics

In other news, major shareholder Shinyaku Co Ltd Nippon acquired 2,798,507 shares of the stock in a transaction that occurred on Friday, September 20th. The shares were purchased at an average cost of $5.36 per share, for a total transaction of $14,999,997.52. Following the transaction, the insider now directly owns 7,090,351 shares in the company, valued at approximately $38,004,281.36. This represents a 65.21 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. 12.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Capricor Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Main Street Financial Solutions LLC lifted its holdings in Capricor Therapeutics by 37.5% in the second quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock valued at $131,000 after acquiring an additional 7,500 shares during the period. SG Americas Securities LLC acquired a new stake in Capricor Therapeutics in the third quarter valued at $133,000. Rhumbline Advisers acquired a new stake in Capricor Therapeutics in the second quarter valued at $147,000. The Manufacturers Life Insurance Company acquired a new position in shares of Capricor Therapeutics during the 3rd quarter worth $161,000. Finally, Sassicaia Capital Advisers LLC acquired a new position in shares of Capricor Therapeutics during the 3rd quarter worth $192,000. Institutional investors and hedge funds own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.